

New criteria for granting a TUE starting on January 1st, 2011

A.

Different way for application of the glucocorticosteroids depends on the route of their administration. In cases of local application there is no longer required the Declaration of Use. Local application means use of liniments, creams, eye- or ear-drops, inhalant spray for dNU therapy, vapours for treatment of the difficulties respiratory, interarthral applications, targeted injections to peritenon and targeted applications to nervus vicinity.

If an application influences organism as a whole, it is required to submit TUE application. Such application of glucocorticosteroids is for example administration of medicaments as tablets, IV injections, intramuscular injections or rectal applications. The filled-out TUE application form has to be accompanied by the well documented medical condition backed up by copies of the laboratory investigations and biochemical findings.

B.

When treating asthma bronchitis, EIB, EIA, salbutamol (Ventolin, Buventol, Ecosal easi-breathe, etc.) and salmeterol (also in combination with glucocorticosteroid – Duaspir and Seretide, separately Serevent) when taken by inhalation at therapeutic doses are no longer on the prohibited list.

Alternate beta 2 agonists such as formeterol (Symbicort, Formesco, Formodual etc.), and terbutaline (Bricanyl) are prohibited and need a TUE from the relevant ADO. The request for a TUE should include a complete medical file with a clear explanation of why an alternate medication is being prescribed. The file should include a copy of the functional respiration investigation that exhibits breathing disruption and its influence by beta 2 agonist.

Dr. Tomáš Paul

Therapeutic Use Committee (TUEC) by CADC